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Abstract: 1 ESGE/EASL recommend that, as the primary diagnostic modality for PSC, magnetic res-
onance cholangiography (MRC) should be preferred over endoscopic retrograde cholangiopancreatogra-
phy (ERCP).Moderate quality evidence, strong recommendation. 2 ESGE/EASL suggest that ERCP
can be considered if MRC plus liver biopsy is equivocal or contraindicated in patients with persisting
clinical suspicion of PSC. The risks of ERCP have to be weighed against the potential benefit with
regard to surveillance and treatment recommendations.Low quality evidence, weak recommendation. 6
ESGE/EASL suggest that, in patients with an established diagnosis of PSC, MRC should be consid-
ered before therapeutic ERCP.Weak recommendation, low quality evidence. 7 ESGE/EASL suggest
performing endoscopic treatment with concomitant ductal sampling (brush cytology, endobiliary biop-
sies) of suspected significant strictures identified at MRC in PSC patients who present with symptoms
likely to improve following endoscopic treatment.Strong recommendation, low quality evidence. 9 ES-
GE/EASL recommend weighing the anticipated benefits of biliary papillotomy/sphincterotomy against
its risks on a case-by-case basis.Strong recommendation, moderate quality evidence.Biliary papilloto-
my/sphincterotomy should be considered especially after difficult cannulation.Strong recommendation,
low quality evidence. 16 ESGE/EASL suggest routine administration of prophylactic antibiotics before
ERCP in patients with PSC.Strong recommendation, low quality evidence. 17 EASL/ESGE recommend
that cholangiocarcinoma (CCA) should be suspected in any patient with worsening cholestasis, weight
loss, raised serum CA19-9, and/or new or progressive dominant stricture, particularly with an associated
enhancing mass lesion.Strong recommendation, moderate quality evidence. 19 ESGE/EASL recommend
ductal sampling (brush cytology, endobiliary biopsies) as part of the initial investigation for the diagnosis
and staging of suspected CCA in patients with PSC.Strong recommendation, high quality evidence.
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This Guideline is an official statement of the European Society
of Gastrointestinal Endoscopy (ESGE) and of the European As-
sociation for the Study of the Liver (EASL) on the role of
endoscopy in primary sclerosing cholangitis. The Grading of
Recommendations Assessment, Development and Evaluation
(GRADE) system was adopted to define the strength of re-
commendations and the quality of evidence.
Introduction
Primary sclerosing cholangitis (PSC) is a chronic bile duct disease
with an estimated prevalence in the range of 1 to 16 per 100 000
with significant regional differences across Europe. The preval-
ence of PSC is increased in patients with ulcerative colitis and es-
timated to be in the range 1%–5% [1]. Magnetic resonance ima-
ging (MRI) studies have shown that the prevalence of imaging
changes compatible with PSC in ulcerative colitis is almost four-
fold higher than that detected based on clinical assessments [2].
PSC is more common in men (comprising 60%–70% of patients)
and most patients present with pancolitis, often with a right-si-
ded predominance [3–5]. A major challenge in the clinical man-
agement of patients is a highly increased and unpredictable risk
of biliary and colonic malignancies.
The diagnosis of PSC is based on the combination of clinical,
laboratory, imaging, and histological findings. Briefly, a diag-
nostic work-up for PSC should be performed in all patients
with inflammatory bowel disease (IBD) and abnormal liver bio-
chemistry test findings, especially elevated alkaline phospha-
tase (ALP) and gamma glutamyl transferase (GGT) values, as
well as in non-IBD patients with elevated cholestatic liver en-
zymes not otherwise explained. A proposed algorithm for PSC
diagnosis has already been presented by earlier European Asso-
ciation for the Study of the Liver (EASL) guidelines [6], and com-
prehensive discussion of issues unrelated to the use of endos-
copy in PSC will not be addressed in the present Guideline.
Endoscopic retrograde cholangiopancreatography (ERCP)
plays a significant role in the handling of PSC because of its
high accuracy and prognostic value as well as its sampling and
therapeutic possibilities. However, ERCP must be integrated
within well-defined clinical algorithms together with less inva-
sive or noninvasive imaging and biochemical tests. In particul-
ar, the widespread implementation of magnetic resonance
cholangiography (MRC) has led to increasing restriction of the
use of ERCP to cases where the diagnosis is equivocal or when
sampling or endoscopic treatment are required.
The aim of this evidence- and consensus-based Guideline,
commissioned by the European Society of Gastrointestinal
Endoscopy (ESGE) and the EASL, is to provide practical advice
on how to utilize ERCP and colonoscopy in PSC patients, in or-
der to maximize their benefit and minimize their burden and
adverse events.
Methods
The ESGE and the EASL commissioned this Guideline and ap-
pointed panel representatives from both societies to partici-
pate in the project development. The Guideline development
process included meetings and online discussions among
members of the Guideline committee during January–April
2015 and July 2016. Key questions (see Appendix 1, online-
MAIN RECOMMENDATIONS
1 ESGE/EASL recommend that, as the primary diagnostic
modality for PSC, magnetic resonance cholangiography
(MRC) should be preferred over endoscopic retrograde cho-
langiopancreatography (ERCP).
Moderate quality evidence, strong recommendation.
2 ESGE/EASL suggest that ERCP can be considered if MRC
plus liver biopsy is equivocal or contraindicated in patients
with persisting clinical suspicion of PSC. The risks of ERCP
have to be weighed against the potential benefit with re-
gard to surveillance and treatment recommendations.
Low quality evidence, weak recommendation.
6 ESGE/EASL suggest that, in patients with an established
diagnosis of PSC, MRC should be considered before thera-
peutic ERCP.
Weak recommendation, low quality evidence.
7 ESGE/EASL suggest performing endoscopic treatment
with concomitant ductal sampling (brush cytology, endo-
biliary biopsies) of suspected significant strictures identi-
fied at MRC in PSC patients who present with symptoms
likely to improve following endoscopic treatment.
Strong recommendation, low quality evidence.
9 ESGE/EASL recommend weighing the anticipated bene-
fits of biliary papillotomy/sphincterotomy against its risks
on a case-by-case basis.
Strong recommendation, moderate quality evidence.
Biliary papillotomy/sphincterotomy should be considered
especially after difficult cannulation.
Strong recommendation, low quality evidence.
16 ESGE/EASL suggest routine administration of prophy-
lactic antibiotics before ERCP in patients with PSC.
Strong recommendation, low quality evidence.
17 EASL/ESGE recommend that cholangiocarcinoma (CCA)
should be suspected in any patient with worsening choles-
tasis, weight loss, raised serum CA19-9, and/or new or pro-
gressive dominant stricture, particularly with an associated
enhancing mass lesion.
Strong recommendation, moderate quality evidence.
19 ESGE/EASL recommend ductal sampling (brush cytolo-
gy, endobiliary biopsies) as part of the initial investigation
for the diagnosis and staging of suspected CCA in patients
with PSC.
Strong recommendation, high quality evidence.










































































only) were prepared by the coordinating team. A systematic lit-
erature search in PubMed/MEDLINE and the Cochrane Library
was conducted, using at a minimum the search terms “Primary
Sclerosing Cholangitis” and “Endoscopy,” and “Colonoscopy”
for the part related to the diagnosis and surveillance of IBD in
PSC. Articles were first selected by title, their relevance was
then assessed by review of full-text articles, and publications
with content that was considered irrelevant were excluded. As-
pects related to endoscopy in PSC patients after liver transplan-
tation were omitted. Evidence tables were generated for each
key question, summarizing the quality of the evidence of the
available studies. The entire process was performed according
to the Grading of Recommendations Assessment, Develop-
ment and Evaluation (GRADE) system [7]. Draft proposals
were presented to the entire group for general discussion and
voting, during a plenary meeting held in November 2015.
In May 2016, a compiled manuscript prepared by L.A. and
T.H.K. was sent to all group members. After revisions and
agreement on a final version, the manuscript was submitted
for peer review. The revised manuscript was approved by all au-
thors and the governing boards of ESGE and EASL and was sub-
sequently forwarded to Endoscopy and the Journal of Hepatology
for publication.
Endoscopic diagnosis and surveillance
of PSC
Diagnosis of PSC
Although ERCP has been regarded as the standard of refer-
ence in diagnosing PSC, MRC is now recommended as a first-
line noninvasive imaging method for patients with suspected
PSC that offers comparable accuracy (except in early-stage
PSC restricted to intrahepatic bile ducts, and in the rare cases
of contraindications to MRC) [8–12]. A meta-analysis based on
6 studies using ERCP as a reference method concluded that
MRC has high sensitivity and specificity (0.86 and 0.94, respec-
tively) for the diagnosis of PSC [13]. According to a decision
model comparing different approaches in the work-up of pa-
tients with suspected PSC [14], the strategy of initial MRC, fol-
lowed by ERCP only in selected cases (e. g. ambiguous MRC
findings), is the most cost-effective approach [14, 15].
The ductographic features defining PSC are described below
but a number of other diseases of the biliary tree may present
similar features (▶Table 1). The specificity of the cholangio-
graphic features of PSC without the additional diagnostic clini-
cal and biochemical clues is poor [16].
Of note, the visualization of the distal common bile duct and
the peripheral intrahepatic ducts is still suboptimal using MRC
[10, 12]. One study has suggested that a numerical score calcu-
lated on the basis of three-dimensional MRC may predict pro-
gression of bile duct changes, but the study lacked ERCP refer-
ence [17]. A diagnostic MRC, because of its very high specificity
for the diagnosis of PSC when diagnostic clinical and biochem-
ical clues are present, obviates a confirmatory ERCP unless ther-
apeutic procedures or ductal sampling are indicated [13, 18].
ABBREVIATIONS
ALP alkaline phosphatase





EASL European Association for the Study of the Liver
ECCO European Crohn’s and Colitis Organisation
ERC endoscopic retrograde cholangiography
ERCP endoscopic retrograde cholangiopancreato-
graphy
ESGE European Society of Gastrointestinal Endoscopy
FISH fluorescence in situ hybridization
GGT gamma glutamyl transferase
GRADE Grading of Recommendations Assessment,
Development and Evaluation
HGD high grade dysplasia
IBD inflammatory bowel disease
IDUS intraductal ultrasound
LGD low grade dysplasia
MRC magnetic resonance cholangiography
MRCP magnetic resonance cholangiopancreatography
MRI magnetic resonance imaging
NLR negative likelihood ratio
NPV negative predictive value
NSAID nonsteroidal anti-inflammatory drug
OR odds ratio
PBC primary biliary cholangitis
pCLE probe-based confocal laser endomicroscopy
PLR positive likelihood ratio
POCS peroral cholangioscopy
PPV positive predictive value
PSC primary sclerosing cholangitis
PTBD percutaneous transhepatic biliary drainage
RCT randomized controlled trial
RR relative risk
RECOMMENDATION
1. ESGE/EASL recommend that, as the primary diagnostic
modality for PSC, magnetic resonance cholangiography
(MRC) should be preferred over endoscopic retrograde
cholangiopancreatography (ERCP).
Moderate quality evidence, strong recommendation.
RECOMMENDATION
2. ESGE/EASL suggest that ERCP can be considered if MRC
plus liver biopsy is equivocal or contraindicated in pa-
tients with persisting clinical suspicion of PSC. The risks
of ERCP have to be weighed against the potential benefit
with regard to surveillance and treatment recommenda-
tions.
Low quality evidence, weak recommendation.











































































Whether or not to perform ERCP in patients with high quality
normal findings at MRC depends on the level of clinical suspi-
cion for PSC and on the impact of the diagnosis on patient man-
agement and prognosis. ERCP is regarded as unnecessary in pa-
tients with a low level of clinical suspicion, but it could be con-
sidered in patients with an intermediate or high level of clinical
suspicion, as suggested by a meta-analysis of MRC diagnostic
performance [13]. However, this meta-analysis included only
studies performed prior to 2007. The continuous improvement
in MRC quality due to use of higher magnetic fields, as exempli-
fied by the ability to visualize third- and fourth-order intrahepa-
tic ducts as well as the availability of three-dimensional image
acquisition, is likely to further decrease the probability of ab-
normal ERCP findings in patients with normal MRC results. In
addition, as detailed reports including the clinical, biochemical,
and histological characteristics and outcomes of these patients
with negative MRC but positive ERCP findings are lacking, the
clinical benefit of ERCP can be questioned in this setting. If
high quality MRC images are not available, or in equivocal
cases, it is reasonable to consider patient referral to centers
with known technical expertise with MRC as a first step [19],
followed by liver biopsy. If high quality MRC images and liver
biopsy still cannot definitely exclude or confirm the presence
of PSC, ERCP can be considered in patients with persisting clin-
ical suspicion for the diagnosis, to take advantage of the filling
pressure obtained by the balloon occlusion and the slight su-
periority as to visualization of the extrahepatic bile ducts.
Ductographic criteria for PSC
The first ERCP criteria for ductographic changes in PSC were
published in 1984 by Li-Yeng & Goldberg [20]. Typical changes
seen in PSC consist of minor irregularities of duct contour and
local narrowing with pre-stenotic dilatation (type I), threadlike
narrowings alternating with normal caliber of bile ducts or
slight dilatation (type II), multiple strictures with saccular dila-
tations (type III), and the most advanced changes consisting of
advanced ductal narrowing with resultant lack of filling of the
peripheral ducts (type IV). The classification has later been
modified by Majojie et al. [21] and Ponsioen et al. [22, 23]. The
classification of Ponsioen et al. [23] has been validated and
shown to correlate with patient prognosis (▶Table 2). Another
type of classification is based on evaluation of the grade,
length, and extent of strictures, the degree of bile duct dilata-
tion, and the distribution of lesions [24].
None of the ductographic criteria published are specific for
PSC and the findings must be interpreted in the context of pa-
tient demographic data and the clinical features. Review by
teams with expertise in complex biliary disease is often useful,
as multiple secondary causes of sclerosing cholangitis must be
considered [25] (▶Table 3).
Unusual cholangiographic features
Some PSC patients may present with cystic dilatations of intra-
hepatic bile ducts simulating Caroli’s disease [10]. Of note, the
fusiform and small cystic dilatations of intrahepatic (mostly
peripheral) bile ducts, as observed in patients with congenital
hepatic fibrosis and autosomal recessive polycystic kidney dis-
ease, should not be misdiagnosed as PSC [11].
Another differential diagnosis is the peculiar cholangio-
graphic phenotype of adult forms of ABCB4 /MDR3 deficiency
which may be characterized by large unifocal or multifocal spin-
dle-shaped intrahepatic bile duct dilatations with or without
apparent bile duct stenosis [12, 26]. This diagnosis should be
suspected on familial clustering of excessive gallstone disease
and often a history of prior cholecystectomy at age<40 years
▶Table 1 Classification of secondary sclerosing cholangitis and condi-










































HIV, human immunodeficiency virus; IgG4, immunoglobulin G4.










































































and associated intrahepatic cholestasis of pregnancy, and is
confirmed by ABCB4 genotyping.
In the diagnosis of PSC there is no established role for endo-
scopic techniques beyond ERCP, e. g. brush cytology, ductal
biopsy, cholangioscopy, or confocal laser endomicroscopy. In
selected cases with suspected extrahepatic disease and incon-
clusive MRC findings, endoscopic ultrasound (including IDUS)
and elastography may add information on common bile duct
strictures, wall thickening, and liver fibrosis stage [27–30].
ERCP in established PSC
Deciding on the clinical impact of a bile duct stricture may
be challenging. The “dominant stricture” denomination arose
alongside the term “major stricture” early in the history of
endoscopic management of PSC [31]. The “major” or “domi-
nant” stricture terms were initially used more broadly, pertain-
ing to strictures of the common bile duct and right and left bi-
furcation of the hepatic ducts (extrahepatic PSC lesions), since
these were found to be more prone to clinical events than intra-
hepatic strictures [31, 32]. The precise definition of a dominant
stricture was introduced by Stiehl et al. in 2002 for use in endo-
scopic studies as a severity measure [33, 34], although it em-
ploys a somewhat arbitrary value, depending, for example, on
filling pressure. A number of endoscopic studies, both before
and after 2002, do not apply the diameter criterion strictly
when determining a dominant stricture [35, 36], and focus on
suspected clinical relevance. Determination of the clinical sig-
nificance and potential benefit from endoscopic interventions
should therefore not be based on this definition alone, and the
decision for intervention rather considered as a compound clin-
ical decision.
Multiple dominant strictures can be found in the same pa-
tient (12% in the study by Bjornsson et al.) [34].
Of note, the ERCP definition of a dominant stricture is usual-
ly considered to be not applicable to MRC, in particular in the
extrahepatic ducts, given the insufficient spatial resolution of
MRC [10, 17] and the lack of the hydrostatic pressure that is
present during ERCP.
A complete occlusion cholangiogram should generally be
obtained if an ERCP is performed, because it adds little risk to
the ERCP, decreases variability, and may reveal that a dominant
stricture suspected at MRC is indeed not a stricture [37].
ERCP can be indicated in patients with a confirmed diagnosis
of PSC when changes in clinical, laboratory, and radiological
findings occur during the course of the disease. The purpose is
to make an assessment of the likelihood of the presence of bili-
ary dysplasia as a risk factor for cholangiocarcinoma (CCA) and
to identify biliary strictures amenable to intervention.
(i) Clinical events
In the early stage of PSC, dominant biliary strictures are usually
asymptomatic. Exacerbation of jaundice (not related to liver
failure), episodes of fever and chills suggestive of cholangitis,
or worsening of pruritus are indications for ERCP for the treat-
▶Table 2 Amsterdam classification of cholangiographic changes in primary sclerosing cholangitis (PSC) [23].
Type Intrahepatic Extrahepatic
0 No visible abnormalities No visible abnormalities
I Multiple caliber changes; minimal dilatation Slight irregularities of duct contour; no stricture
II Multiple strictures; saccular dilatations, decreased arborization Segmental strictures
III Only central branches filled despite adequate filling pressure;
severe pruning
Strictures of almost entire length of duct
IV – Extremely irregular margins; diverticulum-like outpouchings
RECOMMENDATION
3. For the diagnosis of PSC, ESGE/EASL do not suggest
routine use of endoscopic techniques other than ERCP
(i. e., endoscopic ultrasound including intraductal ultra-
sound [IDUS], cholangioscopy, confocal endomicros-
copy).
Weak recommendation, low quality evidence.
RECOMMENDATION
4. ESGE/EASL suggest that a dominant stricture at ERCP
should be defined as a stenosis with a diameter of ≤1.5mm
in the common bile duct and/or ≤1.0mm in an hepatic
duct within 2 cm of the main hepatic confluence.
Weak recommendation, low quality evidence.
RECOMMENDATION
5. ESGE/EASL suggest ERCP and ductal sampling (brush
cytology, endobiliary biopsies) should be considered in
established PSC in the case of: (i) clinically relevant or
worsening symptoms (jaundice, cholangitis, pruritus);
(ii) rapid increase of cholestatic enzyme levels; or (iii)
new dominant stricture or progression of existing domi-
nant strictures identified at MRC in the context of appro-
priate clinical findings.
Weak recommendation, low quality evidence.











































































ment of dominant strictures and to perform ductal brush sam-
pling to exclude malignancy [8, 38]. Worsening pain in the right
upper abdominal quadrant, fatigue, and weight loss also need
careful evaluation.
(ii) Laboratory results
Serum laboratory tests are neither sensitive nor specific enough
to evaluate PSC progression [38], but in the case of rapid in-
crease of serum bilirubin levels and/or cholestatic liver enzymes
(serum ALP, serum GGT) ERCP is indicated [6], especially in
patients with a diagnosis of clinically significant hilar or extra-
hepatic strictures on MRC. Elevation of serum CA19-9 in PSC
patients has an unsatisfactory sensitivity (14%) and positive
predictive value (PPV) (67%) for the diagnosis of CCA [36, 38,
39], and is not helpful in selecting patients for ERCP.
(iii) Progression/new-onset clinically significant strictures
on MRC
Progressive intrahepatic or extrahepatic bile duct dilatation on
imaging studies (ultrasound or MRC) is an indication for ERCP
with ductal sampling [6]. A careful evaluation of new-onset
dominant strictures in PSC is recommended, because of the in-
creased risk of CCA in this situation.
In detail, a stricture that is disproportionately severe relative
to others, concomitant biliary filling defects, marked biliary di-
latation (≥2cm for the common bile duct, ≥1 cm for the right
or left intrahepatic ducts, ≥5mm for other intrahepatic ducts)
suggests CCA [40]. Conversely, this risk was low in patients
without dominant strictures according to a 25-year experience
[41]. Abnormal cytological findings, such as suspicion of malig-
nancy or aneuploid DNA findings need a close follow-up by
ERCP with repeated sampling, unless urgent liver transplanta-
tion is considered to be warranted.
The utility of ERCP in handling dominant strictures was
shown in a prospective study [42] on 171 PSC patients followed
for 20 years: repeated endoscopic therapy was associated with
a transplant-free survival of 81% at 5 years and 52% at 10 years
after initial endoscopic therapy. In this population, a 6% CCA
rate was found in patients with dominant strictures.
MRC may be useful to confirm the indication, to exclude fo-
cal parenchymal changes, and to give the clinicians performing
the ERCP imaging-based guidance to minimize the risk of com-
plications. Regarding MRC in established PSC, a retrospective
single-center study reported a 76% accuracy of MRC in the di-
agnosis of CCA complicating PSC [40]. For these reasons, pa-
tients with an established diagnosis of PSC should have an
MRC examination in their clinical records [13, 43].
Selected series reporting on endoscopic treatment in PSC
patients are summarized in ▶Table 4; none of these compared
performance versus no performance of endoscopic treatment
for dominant stricture. The benefits reported following dilation
of dominant stricture included short-term improvement of
symptoms and of liver biochemical test results, as well as a
longer liver transplantation-free survival compared to that pre-
dicted using the Mayo clinical risk model. Similar findings have
also been reported in several smaller case series [32, 47–50].
The main criticisms of these studies are as follows:
a) The Mayo clinical risk model was not designed to evaluate
patients with dominant stricture; specifically, many patients
underwent therapeutic ERCP because of elevated bilirubin,
which is part of the Mayo risk score and went down in most
patients after the intervention. Hence, baseline Mayo risk
score was not determined in a steady-state situation.
b) Serum test results for cholestasis may spontaneously fluc-
tuate in patients with PSC complicated or not with a domi-
nant stricture. In 125 PSC patients, Bjornsson et al. reported
changes in serum ALP and serum bilirubin from baseline up
to 12 months following ERCP. As patients with dominant
▶Table 3 Characteristic cholangiographic features in primary
sclerosing cholangitis (PSC) and other ductal diseases.
Diagnosis Main cholangiographic features
PSC Multifocal intrahepatic and extrahepatic
bile duct strictures (“beaded” appearance),
slight biliary dilatation, diverticular out-




Multiple intrahepatic bile duct strictures,
stones, biliary abscesses
Ischemic cholangitis Proximal intrahepatic bile duct strictures,
bile duct necrosis, biliomas, abscesses,
biliary cast
Caustic cholangitis Localized intrahepatic bile duct strictures,
irregularities of bile duct wall
AIDS-related
cholangitis




Multifocal central bile duct strictures, bile
duct wall thickening with visible lumen,
pancreatic abnormalities compatible with
autoimmune pancreatitis
Portal biliopathy Central and extrahepatic bile duct
irregularities
RECOMMENDATION
6. ESGE/EASL suggest that, in patients with an estab-
lished diagnosis of PSC, MRC should be considered before
therapeutic ERCP.
Weak recommendation, low quality evidence.
RECOMMENDATION
7. ESGE/EASL suggest performing endoscopic treatment
with concomitant ductal sampling (brush cytology, endo-
biliary biopsies) of suspected significant strictures identi-
fied at MRC in PSC patients who present with symptoms
likely to improve following endoscopic treatment.
Strong recommendation, low quality evidence.










































































stricture received no stricture dilation, the authors stated
that “If our patients had been consequently dilated or sten-
ted the decrease in bilirubin and clinical features at follow-
up would have been attributed to endoscopic therapy” [34].
However, in that study, the variations reported in ALP and in
total serum bilirubin after versus before ERCP were not sig-
nificant, in contrast with various studies listed in ▶Table 4
that used dominant stricture dilation/stenting. Also, it was
not clear on what basis these patients were treated conser-
vatively, while others did receive endoscopic therapy.
Other limitations of most studies listed in ▶Table 4 include ret-
rospective design, selection bias, and reporting of results for a
mixture of treatments, namely dilation with and without stent-
ing of dominant strictures as well as, in a minority of patients,
treatment with ursodeoxycholic acid started during follow-up.
A critical issue is that potential benefits must be weighed
against the certain risks of therapeutic ERCP in patients with
no other therapeutic option except liver transplantation. Symp-
toms likely to improve following dominant stricture treatment
generally include pruritus, pain, cholangitis, and jaundice in pa-
tients with a significant (≥20%) increase in cholestasis, while in
patients with end-stage liver disease, only cholangitis is expect-
ed to improve.
Finally, patients with advanced liver disease with cirrhosis
may not benefit from endoscopic treatment. Ahrendt et al. re-
ported no change in serum bilirubin at 1 year following endo-
scopic and/or percutaneous stricture dilation in 10 patients
with cirrhosis and a baseline serum bilirubin ≥5mg/dL [51].
Death following endoscopic balloon dilation of dominant stric-
ture has been reported in a patient with PSC and end-stage liver
disease [46]. Diagnostic ERCP was followed by deterioration of
cholestasis in 7 of 8 patients with more advanced PSC at biopsy
(Ludwig stage III or IV) versus 1 of 7 with less advanced disease
(Ludwig stage I or II) [52].
Balloon dilation versus stent therapy
Results from selected series reporting on endoscopic treat-
ment of dominant strictures in PSC are summarized in ▶Table
4. Of note: (i) in the majority of studies that reported on bal-
loon dilation for dominant stricture, stents were inserted in a
minority of patients; (ii) a significant improvement in liver
transplantation-free survival compared with the Mayo model
has been reported only with balloon dilation; and (iii) the per-
foration rate has been higher with stenting compared with bal-
loon dilation.
A single retrospective study compared balloon dilation ver-
sus balloon dilation combined with stenting for dominant stric-
ture in PSC patients (n =34 and n=37, respectively) [46]. The
“balloon dilation alone” group was treated by endoscopic
means only, while 23 patients (62%) in the “stenting” group un-
derwent percutaneous treatment because of failed endoscopic
access and/or dominant stricture dilation. Serum bilirubin de-
creased similarly in both groups of patients, but more proce-
dures and more complications were recorded in the stent ver-
sus the balloon dilation group (median number of procedures
per patient, 5.0 vs. 2.1, respectively; patients with complica-
tions, 54% vs. 15%, respectively). Complications included bile
duct perforation in 7 patients (10%), 5 of whom were in the
stent group.However, it is difficult to draw conclusions because
of the different access routes used (percutaneous in 62% in the
stent group vs. 0 in the balloon dilation group), a selection bias
due to more severe stricture in the stent group, and the long
stenting duration used (mean 3 months) putting the patient at
high risk for stent clogging and cholangitis. A short stenting
duration (see recommendation 13) is currently the standard of
care.
The European multicenter randomized DILSTENT trial com-
paring single-balloon dilatation versus short-term stenting was
prematurely stopped recently after a planned interim analysis.
Preliminary results show no differences in outcome, but a sig-
nificantly higher serious adverse event rate in the stent group
(Dr. C.Y. Ponsioen, personal communication).
Role of sphincterotomy
Biliary sphincterotomy was performed routinely as part of
the endoscopic treatment of dominant stricture in some stud-
ies [46] while its use was restricted to specific cases such as
stone extraction and difficulties in stent insertion in other stud-
ies. For example, in 32 PSC patients treated with stents for
dominant stricture, sphincterotomy was performed in 12 pa-
tients (38%) [36] while in another study of dominant stricture
dilation with/without stenting, sphincterotomy was performed
in 63% of 63 patients [44].
Generally, biliary sphincterotomy is not recommended as a
routine procedure prior to biliary stenting because of the asso-
ciated risks as demonstrated in randomized controlled trials
(RCTs) [53]. However, if cannulation is difficult, biliary sphinc-
terotomy is advised, bearing in mind that these patients are
likely to require multiple procedures. Many endoscopists prefer
a small sphincterotomy in PSC in order to avoid ascending cho-
langitis.
Specifically in PSC, biliary sphincterotomy was independent-
ly associated with an increased risk of short-term adverse
RECOMMENDATION
8. ESGE/EASL suggest that the choice between stenting
and balloon dilation should be left to the endoscopist’s
discretion.
Weak recommendation, low quality evidence.
RECOMMENDATION
9. ESGE/EASL recommend weighing the anticipated ben-
efits of biliary papillotomy/sphincterotomy against its
risks on a case-by-case basis.
Strong recommendation, moderate quality evidence.
Biliary papillotomy/sphincterotomy should be considered
especially after difficult cannulation
Strong recommendation, low quality evidence.











































































▶Table 4 Selected series reporting on endoscopic treatment of dominant strictures in primary sclerosing cholangitis.
First author,
Year [ref.]









(8mm in CBD, 6–8mm
for IHBD), plus stent in








▪ At 2 weeks, mean bilirubin level significantly decreased (by 56%)
▪ Improvement in symptoms and liver transplantation-free survival
▪ Comparison with Mayo model not reported (5-year and 10-year
liver transplantation-free survival, 81% and 52%)











▪ Higher proportion of patients alive with no liver transplantation
at 3 and 4 years than predicted using Mayo model (P <0.05); at 1
and 2 years survival similar to Mayo prediction







(8mm in CBD, 6–8mm for
IHBD), plus stent in
5 patients with severe
cholestasis and bacterial
cholangitis
Bilirubin and liver enzymes




▪ At 2 weeks, significant decrease in liver enzymes and bilirubin
▪ Improvement of jaundice in 24 /24 and of pruritus in 12/13
patients
▪ Longer liver transplantation-free survival than predicted using
1992 Mayo model (P <0.0001)
Baluyut,
2001 [44]




Once per year, with stent






▪ Longer liver transplantation-free survival than predicted using








ful stenting for domi-
nant stricture
1-week stenting (10-Fr




Actuarial curve of re-inter-
vention-free patients
▪ Improvement of symptoms in 83%
▪ Significant decrease in bilirubin (44% had increased conjugated
bilirubin at baseline) and cholestasis enzymes
▪ Re-intervention-free patients (actuarial): 60% at 3 years






Stenting for a median of 3
months (plus 8-mm dilation
in 3 patients)
Change in symptoms and
biochemical tests within
6 months following stent
insertion
Adverse events
▪ Improvement of symptoms in 76%
▪ Significant decrease in bilirubin (52% had increased bilirubin at
baseline) and serum tests for cholestasis
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events in two retrospective studies (odds ratios [OR] 4.7 and
5.0) [54, 55] while previous biliary papillotomy/sphincterotomy
was protective for subsequent ERCPs [54]. Therefore experi-
enced endoscopists perform biliary sphincterotomy in patients
with difficult cannulation in whom ERCP is likely to be repeated
during follow-up.
Balloon dilation
There are no comparative data on the optimal dilation
scheme or balloon diameter for treating dominant strictures.
In the largest prospective study (500 endoscopic balloon dila-
tions in 96 patients), the authors performed stepwise dominant
stricture dilation up to diameters of 8mm and 6–8mm in the
common bile duct and the hepatic ducts, respectively [42].
Bile duct diameter upstream and downstream of the dominant
stricture should be taken into account for selecting the balloon
diameter to avoid dilating to more than the duct diameter. Bal-
loon dilations are usually repeated at intervals of 1 to 4 weeks
up to technical success, for an average of 2–3 balloon dilations
[33, 42, 50]. Technical success has been defined as complete
balloon inflation within the dominant stricture with no waist
observed fluoroscopically, followed by the unobstructed pas-
sage of contrast medium through the dilated biliary segment
to the duodenum [42, 50]. Using this technique, bile duct
perforation was reported in 0.2% of dominant stricture dila-
tions (1% of patients) [42]. In contrast, another study that
used balloons of diameter 4–12mm for dilation reported dila-
tion-related biliary perforations in 3.5% of procedures [44].
Repeat balloon dilation during follow-up after initial treat-
ment (usually consisting of several ERCPs) has been mentioned
in some studies, but no results of the repeat dilation, in terms
























































































































































































































































































































































































































































































































































































































11. ESGE/EASL suggest repeating dilation of relapsing
dominant stricture if: (i) the dominant stricture is regard-
ed as the cause of recurrent symptoms (cholangitis, prur-
itus) or of significant increase in cholestasis; and (ii) the
patient’s response to previous dilations has been satisfac-
tory.
Weak recommendation, very low quality evidence.
RECOMMENDATION
10. ESGE/EASL suggest selecting a balloon caliber of up to
the maximum caliber of the ducts delimiting the stric-
ture.
Weak recommendation, low quality evidence.












































































In all large studies of endoscopic treatment for dominant
stricture, plastic stents measuring 7 to 10 Fr in diameter have
been used, with no reported comparison of the results obtain-
ed with various stent diameters. Specifically, the Amsterdam
group aimed at inserting a single 10-Fr stent, and if this was
not possible at first attempt, it was preceded by 1-week stent-
ing with a 7-Fr stent or insertion of a nasobiliary catheter [36,
56]. The Mayo group used 7–10-Fr stents at the endoscopist’s
discretion [46]. The Indianapolis group did not mention the di-
ameter of stents used [44]. Two 7-Fr stents have typically been
used in patients with multiple bilateral dominant strictures, and
in patients with a hilar stricture extending into the left or right
hepatic duct in order to avoid temporary obstruction of the
contralateral biliary system. In general, the stent caliber and
length must be adapted to the specific biliary tree configura-
tion.
In other diseases, studies have shown that polyethylene
stents provide better short-term (1-month) patency than Te-
flon models and that, in the long term, 10-Fr models provide
longer biliary patency compared with thinner ones (11.5-Fr
models do not provide longer patency) [53].
With respect to balloon dilation prior to stenting, it is cur-
rently unclear whether balloon dilation is beneficial before
stent placement.
Duration of stenting
No comparison of various stenting durations has been iden-
tified in studies reporting on stenting for dominant stricture. A
short stenting duration is currently favored because stents tend
to clog rapidly in PSC patients and similar efficacy results have
been reported with short (1–2 weeks) versus standard (8–12
weeks) stenting duration. Specifically, a retrospective study of
short-term stenting (mean duration 11 days) in 32 symptomat-
ic PSC patients with dominant stricture showed, at 2 months, a
symptomatic improvement in 83% of the patients as well as a
significant improvement of cholestasis test results; at 1 and 3
years, actuarial analysis showed that 80% and 60% of patients,
respectively, would not require re-intervention [36]. Stent dys-
function was not reported in this study but two patients treated
by stent removal developed hydrops of the gallbladder. The
same group of authors had previously reported similar efficacy
results with 3-month stenting in 25 patients with symptomatic
dominant stricture but, in that study, unscheduled stent ex-
change had to be performed on 32 occasions because of sus-
pected stent clogging (cholangitis n =23, jaundice n=9) [45].
All studies mentioned focused on clinical and serum liver
tests, not radiological data, to assess the short-term effect of
therapeutic ERCP [36, 45, 46, 56]. Endoscopic treatment has
been repeated in a sizeable proportion of patients. For exam-
ple, with long median stenting periods (3 months), the median
number of repeated ERCPs per patient ranged between 3 and 5
during follow-up periods of 29 and 22 months in two studies
[45, 46], while following a short stenting period (mean 11
days) repeat ERCP rates at 1 and 3 years after treatment were
estimated at 20% and 40%, respectively [36]. Other details
about repeated treatments were not reported.
In many centers, stents are removed during an esophago-
gastroduodenoscopy without biliary opacification in PSC pa-
tients.
Complications of endoscopic therapy
Several studies have evaluated the risk of complications in
PSC patients undergoing ERCP [33, 35, 44, 49, 54, 55, 57–62]
(▶Table 5). ERCP carries an increased risk for complications
in the context of PSC, especially pancreatitis, cholangitis, and
extravasation of contrast, although not all studies have docu-
mented such an increased risk in PSC [59, 62]. In a systematic
survey [63] of post-ERCP complications associated with var-
ious indications for ERCP, including 21 prospective studies
and 16 855 patients, the total complication rate was 6.85%
(95%CI 6.46%–7.24%). Pancreatitis occurred in 585 patients
(3.47%, 95%CI 3.19%–3.75%). In another large retrospective
single-center study [47], with 11497 procedures over 12
years, the total complication rate was 4.0% and pancreatitis
occurred in 3.6%. The overall risk of adverse events in patients
with PSC has varied in different, much smaller studies, from
1.8% to 18.4% [33, 35, 44, 49, 55, 57–62], which is higher
than reported for other indications [47, 63].
Retraction of the papilla and an altered, more difficult posi-
tion of the endoscope due to hypertrophy of the left liver lobe
may be encountered during ERCP in PSC patients. Whether this
actually influences cannulation success rates has not been in-
vestigated by specific studies. Cohort studies describing PSC
patients provide only limited details on cannulation difficulties,
with failure rates of 0% to 6% [33, 36, 41, 49, 50, 57, 62, 64–
RECOMMENDATION
12. ESGE/EASL suggest selecting a single 10-Fr stent for
dominant stricture in the extrahepatic ducts or two 7-Fr
stents for hilar strictures extending into the left or right
hepatic duct (final stent diameters in the case of stepwise
stenting)
Weak recommendation, very low quality evidence.
RECOMMENDATION
13. ESGE/EASL suggest that stents used for treating
dominant stricture should be removed 1–2 weeks follow-
ing insertion.
Weak recommendation, low quality evidence.
RECOMMENDATION
14. ESGE/EASL suggest that ERCP in PSC patients should
be undertaken by experienced pancreaticobiliary endos-
copists.
Strong recommendation, very low quality evidence.










































































66]. Furthermore, there is likely a selection bias since most ret-
rospective series describing the results of endoscopic treat-
ment have the initiation of therapy as prerequisite, therefore
potentially excluding cannulation failures.
The largest series is the study by Ismail et al. [54]. In this ret-
rospective review of 441 ERCP procedures over a 3-year time
period, primary cannulation success was 88.2%. Of note, in
137 patients (37.8%) a previous biliary sphincterotomy had
been performed. Pancreatic sphincterotomy as an access tech-
nique was used in 11.8% and freehand needle-knife sphincter-
otomy in a further 2.5%. The primary failure rate was 0.5%.
These figures suggest that cannulation in PSC patients may in-
deed be more difficult than in other types of patients.
Post-ERCP pancreatitis
















































































15. ESGE/EASL recommends routine rectal administration
of 100mg of diclofenac or indomethacin immediately be-
fore or after ERCP in all patients without contraindication.
In addition to this, in the case of high risk for post-ERCP
pancreatitis, the placement of a 5-Fr prophylactic pancre-
atic stent should be considered.
Strong recommendation, high quality evidence.











































































Post-ERCP pancreatitis (PEP) is the most common and feared
complication associated with ERCP. The risk for PEP in PSC var-
ies from 1% to 7%, although the diagnostic criteria vary be-
tween studies [67]. Although the quality of the evidence is
low, the factors increasing the risk for PEP are probably not dif-
ferent in PSC patients from those in the general population: fe-
male sex (OR 2.6, P=0.015) and a guidewire in the pancreatic
duct (OR 8.2, P <0.01). Presence of a native papilla increases
the risk whereas previous sphincterotomy decreases it [54],
suggesting that pre-emptive endoscopic papillotomy might be
warranted in PSC patients where repeat procedures might be
anticipated. This has however yet to be proven.
Prolonged papilla contact time, as well as therapeutic proce-
dures such as biliary brush cytology, sphincterotomy, stenting,
and dilation, are associated with increased risk of PEP. Precut
biliary and pancreatic sphincterotomy is markedly associated
with PEP [54], possibly reflecting the difficult cannulation and
prolonged procedure time. A recent Cochrane analysis compar-
ing the contrast-assisted with the guidewire-assisted cannula-
tion technique showed that the guidewire technique both in-
creased the primary cannulation rate and reduced the risk of
PEP, and it appears to be the most appropriate first-line cannu-
lation technique [68].
Rectal nonsteroidal anti-inflammatory drugs (NSAIDs). In
its 2014 update to a Guideline on the prophylaxis of PEP, ESGE
recommends routine rectal administration of 100mg of diclo-
fenac or indomethacin immediately before or after ERCP in all
patients undergoing ERCP who were without contraindication
to NSAIDs [69]. The recommendation was supported by the re-
sults of six meta-analyses published between 2009 and 2014
that compared NSAIDs versus placebo administration for pro-
phylaxis of post-ERCP pancreatitis. These meta-analyses con-
cordantly showed the benefit of NSAIDs in preventing either
mild or moderate/severe PEP. These results were further sup-
ported by subsequent meta-analyses [70, 71] and the cost-effi-
ciency of this approach has been demonstrated [72]. This re-
commendation applies to PSC patients.
Pancreatic stenting: The ESGE 2014 recommendation on
prophylactic pancreatic stenting was supported by: (i) three
meta-analyses of RCTs that showed a significant reduction in
the incidence and the severity of PEP when prophylactic pan-
creatic stenting was used; and (ii) a study showing that pancre-
atic stent placement is cost-effective only in patients/proce-
dures at high risk for post-ERCP pancreatitis.
The following conditions relevant to PSC are considered to
represent high risk for PEP: precut biliary sphincterotomy, pan-
creatic guidewire-assisted biliary cannulation, endoscopic bal-
loon sphincteroplasty, pancreatic sphincterotomy, and pres-
ence of more than three of the following risk factors: female
gender, previous pancreatitis, younger age, nondilated extra-
hepatic bile ducts, absence of chronic pancreatitis, normal se-
rum bilirubin, duration of cannulation attempts > 10min, >1
pancreatic guidewire passage, pancreatic injection, failure to
clear bile duct stones, intraductal ultrasound.
Bacterial cholangitis and bacteriobilia are a not infrequent
finding among patients with PSC. In studies evaluating the
complications of ERCP in PSC the risk for cholangitis has varied
from 0.25% to 8% [33, 35, 44, 49, 54, 55, 57–62] depending on,
among other items, the criteria used to define cholangitis. The
use of prophylactic antibiotics varies markedly between stud-
ies, in terms of prevalence, type of antibiotic, and duration of
administration (from 1 oral dose before the procedure to
1-week dosing afterwards). In a Cochrane meta-analysis (9
RCTs, 1573 patients), the prophylactic use of antibiotics was
shown to prevent cholangitis (relative risk [RR] 0.54, 95%CI
0.33–0.91), septicemia (RR 0.35, 95%CI 0.11–1.11), bactere-
mia (RR 0.50, 95%CI 0.33–0.78), and pancreatitis (RR 0.54,
95%CI 0.29–1.00). It was concluded that prophylactic antibio-
tics reduce bacteremia and seem to prevent cholangitis and
septicemia in patients undergoing elective ERCP [73]. Our re-
commendation is in line with the American Society for Gastro-
intestinal Endoscopy (ASGE) recommendation to prescribe an-
tibiotic prophylaxis in procedures where drainage achieved at
ERCP is incomplete or achieved with difficulty, such as in PSC
[74]. Bile fluid sampling could be considered during ERCP, to
guide antibiotic treatment in case cholangitis occurs despite
the prophylaxis [75].
PSC and cholangiocarcinoma
PSC is associated with a markedly increased risk for CCA with
a lifetime risk of 10%–20% [76, 77], or up to 400-fold compar-
ed with the general population [78]. CCA represents a common
cause of death among PSC patients [79], whereby 27%–50% of
all CCAs are detected within 1 year of a PSC diagnosis [41, 78,
80] depending on the indications for ERCP.
RECOMMENDATION
17. EASL/ESGE recommend that cholangiocarcinoma
(CCA) should be suspected in any patient with worsening
cholestasis, weight loss, raised serum CA19-9, and/or
new or progressive dominant stricture, particularly with
an associated enhancing mass lesion.
Strong recommendation, moderate quality evidence.
RECOMMENDATION
18. A raised serum CA19-9 may support the diagnosis of
CCA, but has a poor specificity.
Weak recommendation, low quality evidence.
RECOMMENDATION
16. ESGE/EASL suggest routine administration of prophy-
lactic antibiotics before ERCP in patients with PSC.
Strong recommendation, low quality evidence.










































































CCA should be suspected in PSC patients experiencing rapid
deterioration of liver function test findings, increasing jaun-
dice, weight loss, and abdominal pain. However, the develop-
ment of such a clinical trend may also suggest an advanced
form of CCA. An observational study performed in the US on
230 patients affected by PSC, 23 of whom had CCA, showed
no major differences in clinical features between patients with-
out CCA and those with CCA at an earlier stage [40].
Increased serum CA19-9 levels have been reported to in-
dicate the development of CCA in PSC patients. Cutoff levels
of 129 or 100 U/mL detected CCA with high sensitivity (nearly
80%) and specificity (nearly 100%) [81], but only in advanced
cases of CCA. These data are in contrast with other observa-
tions that showed that one third of PSC patients with high
CA19-9 levels did not have CCA [82, 83]. In a recent study per-
formed on 433 PSC patients, 41 of whom had biliary malignan-
cy, the use of FUT2 /3 genotype-dependent cutoff values for
CA19-9 improved sensitivity and reduced the number of false-
positive results [84]. In a study screening for biliary dysplasia
using ERCP and brush cytology, serum CA19-9 had no prognos-
tic value for biliary dysplasia or CCA [37].
Currently, there are no definite radiologic features that indi-
cate CCA in a PSC patient, although the detection of a domi-
nant stricture by MRC may be suggestive for CCA. However,
50% of PSC patients experience a dominant stricture and its ab-
sence does not rule out CCA. In a cohort of 230 patients, ultra-
sound, computed tomography (CT), and MRCP were found to
have high specificity but low sensitivity (10%–32%) [40].
ERCP findings indicative of CCA
Dominant strictures are frequent in PSC [42] and do not per se
indicate development of a malignancy. In a large single-center
study, CCA was seen in 6/95 dominant strictures (6%). In gener-
al it could be inferred that the chance of any dominant stricture
of harboring a CCA is around 5%. Most CCAs develop in the
perihilar region or in extrahepatic bile ducts, and are reachable
with a cytological brush. In a large series of patients with CCA
[85], 50% had perihilar cancers, 42% had distal cancers, and
only 8% were intrahepatic CCAs. No specific imaging features
have been found to differentiate benign strictures from malig-
nant ones. Based on ERCP findings only, it is not possible to ex-
clude CCA from benign strictures caused by PSC, and the diag-
nosis always requires additional techniques such as imaging or
biliary cytology or histology.
Brush cytology
Bile duct brushing is the most common method for tissue
sampling in patients with PSC for detecting inflammation, bili-
ary dysplasia or CCA (▶Table 6, ▶Table 7). In a recent meta-
analysis (11 studies, 747 patients) [95], the pooled diagnostic
values of bile duct brushing for diagnosis of CCA in patients
with PSC were: sensitivity 43% (95%CI 35%–52%), specificity
97% (95%–98%), PPV 78.2% (63.6%–86.7%), and negative
predictive value (NPV) 87.2% (85.4%–89.1%). The authors
concluded that bile duct brushing is a simple and highly
specific technique for detecting CCA in patients with PSC.
However, the modest sensitivity from bile duct brushing pre-
cludes its utility as a diagnostic tool for early detection of
CCA in patients with PSC. In a recent study of 261 mostly
asymptomatic (81%) patients with PSC, who had been referred
for their first ERC to confirm the diagnosis and to screen for
biliary dysplasia with systematic bile duct brushings, 43%
were found to have advanced disease, and malignant/suspi-
cious cytology was present in 6.9% [37].
Addition of FISH analysis of cytology specimens enhanced
the sensitivity for detecting CCA in patients with PSC in several
patient series [39, 40, 93, 94]. The ideal modality (e. g. FISH vs.
digital image analysis vs. flow cytometry) and the appropriate
threshold values for markers assessed by each of these modal-
ities have not been robustly established, and this makes meta-
analysis of available data challenging [96]. For this reason,
chromosomal assessments can so far only be recommended in
equivocal cases [96]. As DNA technologies evolve, new markers
are likely to emerge.
Ductal biopsy
Ductal biopsy has been shown to improve sensitivity, specifici-
ty, and accuracy in diagnosing CCA compared to brush cytology
alone [99]. Since the sampling area for ductal biopsies is lim-
ited, complementary biliary brushings should be considered in
all patients. In published studies the sensitivity for the detec-
tion of CCA by ductal biopsy varies from 30% to 88% and the
specificity from 97% to 100% [100]. Combined brush cytology
RECOMMENDATION
19. ESGE/EASL recommend ductal sampling (brush cytol-
ogy, endobiliary biopsies) as part of the initial investiga-
tion for the diagnosis and staging of suspected CCA in pa-
tients with PSC.
Strong recommendation, high quality evidence.
RECOMMENDATION
20. ESGE/EASL suggest that fluorescence in situ hybridi-
zation (FISH) or equivalent chromosomal assessments
are considered in patients with suspected CCA when
brush cytology results are equivocal.
Weak recommendation, low quality evidence.
RECOMMENDATION
21. ESGE/EASL suggest that additional investigations
such as cholangioscopy, endoscopic ultrasound, and
probe-based confocal laser endomicroscopy (pCLE) may
be useful in selected cases.
Weak recommendation, low quality evidence.











































































▶Table 6 Detection of biliary malignancy in primary sclerosing cholangitis (PSC) using brush cytology.
First author,
Year [ref]
Study design Intervention Participants,
n
Outcomes Results
Sensitivity Specificity PPV NPV
Ponsioen,
1999 [86]




 60%  89%  59%  89%
Lindberg,
2002 [87]





 71% 100% NA NA
Siqueira,
2002 [88]




 46.4% 100% NA NA
Lal,
2004 [89]




 67%  94%, NA NA
Furmanczyk,
2005 [90]




 62.5% 100% NA NA
Boberg,
2006 [91]




100%  84%  68% 100%
Moff,
2006 [92]




 50%  91% NA NA
Moreno Luna,
2006 [93]
Prospective Brush cytology from
biliary strictures
 86 PSC Detection of
malignancy/CCA
 18% 100% 100%  83%
Charatcharoenwitthaya,
2008, [40]




  8% 100% 100%  89%
Levy,
2008 [39]
Prospective Brush cytology from
biliary strictures
 32 PSC Detection of
malignancy/CCA
  7% 100% NA NA
Halme,
2012 [94]




 46%  88%  86%  52%
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▶Table 7 Detection of biliary malignancy in primary sclerosing cholangitis (PSC) using brush cytology: meta-analyses and reviews.
First author,
Year [ref]



















747 Diagnostic yield of bile
duct brushing in diag-
nosing CCA in PSC
strictures
43%  97% 8.87 0.56 The moderate sensitivity in
detecting CCA, precludes its
utility as a surveillance tool






FISH 629 Diagnostic yield of
FISH in diagnosing
CCA in PSC strictures
31%  71% 1.19 0.95 FISH positivity has reasonable
diagnostic accuracy; however,










51%  93% 6.81 0.56 FISH polysomy is highly




































59% 100% 53.8 0.42 Brushings and biopsy are




Systematic review MRI NA Diagnosing cholan-
giocarcinoma in PSC
NA Lack of evidence
Systematic review CT  45 Diagnosing cholan-
giocarcinoma in PSC
82%  80% 4.10 0.25 CT provides good sensitivity
and specificity in detecting
biliary tract carcinoma
complicating PSC.
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and biopsy has a sensitivity varying from 47% to 86% and spe-
cificity from 97% to 100%. A retrospective study [100] assessed
the accuracy of triple modality testing, namely brush cytology,
biopsy, and FISH, and their combinations, in one patient group,
and the accuracy of brush cytology alone in a separate patient
group. It demonstrated that brush cytology alone had a sensi-
tivity of 42%, specificity 100%, PPV 100%, and NPV 88%. The
triple sample assessment modality markedly improved the
overall sensitivity (82%), with similar specificity (100%), PPV
(100%), and NPV (87%).
Cholangioscopy
Peroral cholangioscopy (POCS) allows direct visualization of
extrahepatic bile duct strictures. The recent development of
video-based systems provides better image resolution and of-
fers clearer views than fiberoptic cholangioscopy. Compared
to ERC and tissue sampling, POCS was shown to improve diag-
nostic accuracy [101–103]. However, these studies were not
focused on CCA in PSC patients.
Single-operator cholangioscopy (SpyGlass) is gaining popu-
larity, primarily for stone treatment and assessment of indeter-
minate strictures. Its utility in PSC was studied in a recent case
series [104], with visual assessment and targeted biopsies of 64
strictures in 47 patients. Only 1 of 3 patients with CCA were di-
agnosed by the ERCP procedure. It is likely that newer digital
versions of this instrument (e. g. SpyGlass DS) will perform bet-
ter, at least in terms of visual diagnostics.
Other techniques
Other techniques such as intraductal ultrasonography and con-
focal laser endomicroscopy have shown potential utility in the
diagnosis of CCA in PSC, but are not established in routine clin-
ical practice. Regular endoscopic ultrasonography with sam-
pling of detectable masses or locoregional lymph nodes is ad-
vocated by some, but such sampling is also regarded as a con-
traindication to liver transplantation in some centers; thus any
such sampling should be discussed with local multidisciplinary
teams.
Endoscopic surveillance of PSC-associat-
ed inflammatory bowel disease (IBD)
The relationship between PSC and IBD is well established [105].
The prevalence of IBD in patients with established PSC varies
widely, but is reported as 80% in Scandinavian countries [106].
The often asymptomatic phenotype of IBD means that preval-
ence data are strongly influenced by the level of proactive
search for the disease. The typical scenario was for IBD to pre-
cede the presentation of PSC. However, the clinical presenta-
tion of IBD is variable, and the disease may be subclinical or
asymptomatic for years [107] and is nowadays often diagnosed
after the recognition of the liver disease. Notably, IBD may have
been present for an unknown period of time when PSC is diag-
nosed. The increased risk of colon cancer in PSC-associated IBD
[108, 109] hence makes it crucial to perform a full ileocolono-
scopy at the time of PSC diagnosis in all patients. As to the diag-
nosis of IBD per se, complete ileocolonoscopy is critical since
rectal sparing, as well as right-sided involvement, is frequent
in these patients [8].
Timing of screening
Based on initial screening, subsequent surveillance can be
planned. If IBD is documented, annual colonoscopies are war-
ranted [6, 110] since it has been shown that PSC-IBD patients
whose colorectal cancer (CRC) is detected in a surveillance pro-
gram have a significantly lower risk of CRC-related mortality as
compared to non-surveilled patients [78]. If not, repeat colo-
noscopy should be done with the occurrence of symptoms sug-
gestive of IBD, or of elevated F-calprotectin, or otherwise at 3–
5 years [111], although this recommendation lacks any scienti-
fic evidence beyond extrapolation from general IBD recommen-
dations [112].
Endoscopic modality
PSC-associated colitis seems to be distinctive from other
IBD: colitis is predominant in the right colon [113] and colon
cancer is typically right-sided [114]. Lack of inflammation in
the rectum (“rectal sparing”) is reported in some studies but
less frequently observed in others [3]. Endoscopic surveillance
RECOMMENDATION
22. ESGE/EASL recommend screening ileocolonoscopy at
the time of PSC diagnosis.
Strong recommendation, high quality evidence.
If IBD is documented endoscopically or histologically, an-
nual surveillance colonoscopies are warranted.
Strong recommendation, low quality evidence.
RECOMMENDATION
23. ESGE/EASL suggest that if no IBD is documented, the
next ileocolonoscopy should be considered at 5 years or
whenever bowel complaints suggestive of IBD occur.
Weak recommendation, low quality evidence.
RECOMMENDATION
24. For screening for the presence of IBD, EASL/ESGE re-
commend ileocolonoscopy with four-quadrant biopsies
from all colonic segments and the terminal ileum.
Strong recommendation, low quality evidence.
RECOMMENDATION
25. For dysplasia surveillance of PSC-associated IBD,
EASL/ESGE recommend ileocolonoscopy with dye-based
chromoendoscopy with targeted biopsies.
Strong recommendation, low quality evidence.










































































of PSC-associated colitis is presumed to increase the chance of
early detection of dysplasia or malignancy [115].
Screening for IBD at diagnosis of PSC is best performed by
high definition ileocolonoscopy with four-quadrant biopsies
from all colonic segments and the terminal ileum. Biopsies
should be taken at the index endoscopy even without macro-
scopic signs of inflammation [111, 116, 117].
In established PSC-IBD, ileocolonoscopy with dye-based
chromoendoscopy (0.1% methylene blue or 0.1%–0.5% indigo
carmine) with targeted biopsies is required for neoplasia sur-
veillance of PSC-associated IBD. In appropriately trained hands,
in the situation of quiescent disease activity and adequate bow-
el preparation, nontargeted four-quadrant biopsies can be
abandoned [118]. This approach is also endorsed by the Euro-
pean Crohn’s and Colitis Organisation (ECCO) [112]. It should
be noted that there are no studies on colonic neoplasia surveil-
lance specifically in the setting of PSC-associated IBD.
Routine use of pancolonic chromoendoscopy with targeted
biopsies for neoplasia surveillance in patients with long-stand-
ing colitis (disease duration of > 8 years) increased the propor-
tion of patients found with dysplasia by a factor of 2.1–3.3
compared to standard definition videocolonoscopy. For the de-
tection of patients with neoplasia, the pooled incremental yield
of conventional chromoendoscopy with random biopsies over
standard white-light endoscopy with random biopsies was 7%
(95%CI 3.2%–11.3%) [119]. The benefit of conventional chro-
moendoscopy over white-light endoscopy with latest-genera-
tion high definition colonoscopes is unknown to date.
Handling of polyps and colorectal dysplasia
Colorectal cancer (CRC) risk is significantly increased in pa-
tients with coexisting IBD and PSC. A meta-analysis of 11 stud-
ies concluded that patients with ulcerative colitis and PSC were
at increased risk of developing CRC compared to patients with
ulcerative colitis alone (OR 4.09; 95%CI 2.89–5.76) [109]. A re-
cent large population-based study in the Netherlands found a
9-fold increased risk of developing CRC in PSC-ulcerative colitis
patients, compared to the age- and gender-matched popula-
tion (standardized incidence ratio [SIR] 8.6, 95%CI 3.5–17.7),
and a 10-fold increased risk, compared to ulcerative colitis con-
trols (ratio of SIRs 9.8, 95%CI 1.9–96.6) [78].
Most dysplasia is visible at colonoscopy [120, 121]. On the
other hand, invisible dysplastic lesions can also be diagnosed
by random biopsies during surveillance. According to the IBD
Dysplasia Morphology Study Group [122], dysplasia is subdivi-
ded into LGD and HGD.
Recent ECCO guidelines state that a visible lesion with dys-
plasia should be completely resected endoscopically irrespec-
tive of the grade of dysplasia or the location relative to the in-
flamed mucosal areas [112]. Subsequently, the surrounding
mucosa (around the visible lesion) should be examined (with
chromoendoscopy-guided targeted biopsies or random biop-
sies if chromoendoscopy is not available). If endoscopic resec-
tion is incomplete or impossible, or if dysplasia is detected in
the surrounding mucosa, total proctocolectomy is recommen-
ded.
In the case of invisible lesions with LGD, urgent repeat chro-
moendoscopy should be performed, to eventually identify a
well-circumscribed lesion and/or perform additional random
biopsies. If the presence of LGD is confirmed, there is no clear
consensus regarding management; proctocolectomy or sur-
veillance could be recommended. Actually, two studies re-
vealed a significant 5-year progression rate (33%–54%) of LGD
to HGD [123, 124], whereas others showed low progression
rates [125, 126]. Finally, in the case of invisible lesions with
HGD or adenocarcinoma, total proctocolectomy is indicated.
This Guideline from ESGE and EASL represents a consensus
of best practice based on the available evidence at the time of
preparation. The recommendations might not apply in all situa-
tions and should be interpreted in the light of specific clinical
situations and resource availability. Further controlled clinical
studies may be needed to clarify aspects of the Guideline, and
revision may be necessary as new data appear. Clinical consid-
erations may justify a course of action at variance to these re-
commendations. This ESGE/EASL Guideline is intended to be
an educational device to provide information that may assist
endoscopists in providing care to patients. It is not a set of rules
and should not be construed as establishing a legal standard of
care or as encouraging, advocating, requiring, or discouraging
any particular treatment.
RECOMMENDATION
26. ESGE/EASL recommend endoscopic resection of any
visible lesions and assessment of the surrounding muco-
sa. We recommend proctocolectomy in the case of dys-
plasia in the surrounding mucosa, or when the lesion can-
not be completely resected. Otherwise, repeat colonos-
copy and close follow-up is warranted.
Strong recommendation, low quality evidence.
RECOMMENDATION
27. In the case of invisible lesions with high grade dyspla-
sia (HGD) confirmed by two expert pathologists, procto-
colectomy should be advised
Strong recommendation, low quality evidence.
RECOMMENDATION
28. In the case of invisible lesions with low grade dysplasia
(LGD) confirmed by two expert pathologists, repeat colo-
noscopy after 3 months with chromoendoscopy is recom-
mended.
Strong recommendation, low quality evidence.
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